SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Politics : Politics for Pros- moderated
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DewDiligence_on_SI who wrote (606733)9/2/2016 12:51:07 PM
From: Thehammer  Read Replies (2) of 793669
 
Well, FDA had some reason for denying Teva's application for a generic version of EpiPen. If you reject the speculation posited in the SeekingAlpha write-up, does it mean that you subscribe to the (nutty, IMO) notion that FDA is involved in some kind of conspiracy to help Mylan?


Dew,



Very much appreciate your comments and insights in the Biotech arena. I lurk on many of those threads. Currently, I follow over 200 companies and invest a relatively small portion in the Biotech space. I don't follow Mylan but realize they have been involved in a lot of M&A activity over the past few years and that Teva tried to acquire them awhile back. I have a minor spec position in ATRS which makes the delivery device for TEVa generic potential offering to the EPIPen so I have followed that saga and that company certainly qualifies ad the gang that couldn't shoot straight.

Based on some of my readings in that regard Mylan fought the generic on multiple fronts such as filing citizen's petitions and legally. I have also read probably somewhere on SA that a study was done on the use of the EpiPen and that folks tended to forget how to use it and needed to be retrained after 3 months.

I have allergies that require shots monthly at Barnes (BJC) in STL. They make me sit around for 20 minutes to see if I have a reaction, but never have. One time, I sat in the waiting room for an extended period of time before they gave me my shots. The Allergy Center is a teaching facility in conjunction with Wash U, but the real doctors present had this deer-in-the headlights look. I asked the head nurse and sure enough someone had a severe reaction. The nurse who normally handles my shots was pivotal in handling the situation thus the delay. I imagine that the folks with bee stings and peanut reactions all go to the emergency room and those folks are better able to handle the situation.

I don'y know about conspiracy theories but I'd consider a range of possibilities from extremely poor corporate governance to some level of manipulation:

1) Unless you just dropped off a turnip truck or live under a rock, management of Mylan would have to know that jacking the price of the EpiPen would surely raise many eyebrows and result in negative PR. Witness Martin Shlreli (I sold a position in Retrophin because I figured this guy was a crook) and GILD (who I think is justified in their pricing). Politicians protecting us at every step of the way.

2) The CEO is the daughter of a democrat senator and Myllan donated to the Clinton Foundation

3) Mylan launches their own generic version and provides some pricing relief.

4) Looks like in 2017 in all likelihood generic competition will emerge.

5) The liberally-connected CEO tossed a a softball to HRC and then seemingly reversed course. At the very least she should be fired for being an idiot.


Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News